Details of the Drug

General Information of Drug (ID: DMGEATB)

Drug Name
Siltuximab
Indication
Disease Entry ICD 11 Status REF
Anemia 3A00-3A9Z Approved [1]
Idiopathic multicentric Castlemans disease 2A81.Y Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [3]
Multiple myeloma 2A83 Phase 2 [4]
Castleman's disease 4B2Y Investigative [5]
ATC Code
L04AC11: Siltuximab
L04AC: Interleukin inhibitors
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Antibody
Sequence
>heavy chain
EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYY
PDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSSA
STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS
TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK
>light chain
QIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVR
FSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIKRTVAAPSVFIFPPS
DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL
SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 20.6 days [6]
Vd
The volume of distribution (Vd) of drug is 4.5 L []
Cross-matching ID
UNII
T4H8FMA7IM
DrugBank ID
DB09036
TTD ID
D07NJN
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-6 (IL6) TTT1V78 IL6_HUMAN Not Available [7]
HUMAN interleukin 6 (IL6) TTJH4Y5 IL6_HUMAN Inhibitor [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Anemia
ICD Disease Classification 3A00-3A9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-6 (IL6) DTT IL6 8.08E-01 -0.77 -1.15
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Siltuximab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Oliceridine DM6MDCF Moderate Altered metabolism of Siltuximab due to Oliceridine alters the formation of CYP450 enzymes. Acute pain [MG31] [9]
Levonorgestrel DM1DP7T Moderate Altered metabolism of Siltuximab due to Levonorgestrel alters the formation of CYP450 enzymes. Contraceptive management [QA21] [9]
Oestradiol valerate and dienogest DMZK0FQ Moderate Altered metabolism of Siltuximab due to Oestradiol valerate and dienogest alters the formation of CYP450 enzymes. Endometriosis [GA10] [9]
Levamlodipine DM92S6N Moderate Altered metabolism of Siltuximab due to Levamlodipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [10]
Lurbinectedin DMEFRTZ Moderate Additive immunosuppressive effects by the combination of Siltuximab and Lurbinectedin. Lung cancer [2C25] [10]
GDC-0199 DMH0QKA Moderate Altered metabolism of Siltuximab due to GDC-0199 alters the formation of CYP450 enzymes. Mature B-cell leukaemia [2A82] [10]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Siltuximab and Siponimod. Multiple sclerosis [8A40] [11]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Siltuximab and Ocrelizumab. Multiple sclerosis [8A40] [12]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Siltuximab and Ozanimod. Multiple sclerosis [8A40] [10]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Siltuximab when combined with Anthrax vaccine. Sepsis [1G40-1G41] [13]
⏷ Show the Full List of 10 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7396).
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 125496.
3 ClinicalTrials.gov (NCT04330638) Treatment of COVID-19 Patients With Anti-interleukin Drugs. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014 Aug;15(9):966-74.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
8 Siltuximab. In: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. 2018 Dec 3.
9 Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.
10 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
11 Cerner Multum, Inc. "Australian Product Information.".
12 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
13 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]